Nanotechnology Now - Press Release: NanoPacific Holdings, Inc. Announces Exclusive License from the University of California at Los Angeles for Supramolecular Nanoparticles for Molecular Diagnostics and Therapeutics

Home > Press > NanoPacific Holdings, Inc. Announces Exclusive License from the University of California at Los Angeles for Supramolecular Nanoparticles for Molecular Diagnostics and Therapeutics

Abstract:
NanoPacific Holdings, Inc. (NPH) announces the acquisition of an exclusive license from University of California at Los Angeles (UCLA) for a suite of supramolecular nanoparticle technologies.

NanoPacific Holdings, Inc. Announces Exclusive License from the University of California at Los Angeles for Supramolecular Nanoparticles for Molecular Diagnostics and Therapeutics

Los Angeles, CA | Posted on December 9th, 2009

Under the terms of the agreement between NPH and UCLA, NPH will have an exclusive worldwide license of a system composed of a ternary mixture of modular components that self-assemble into supramolecular nanoparticles. The technology enables the synthesis of new-generation nanoparticles with a high degree of size and morphological control, as well as tunable surface charge and chemistry. These properties enable the production of biodegradable nanoparticles that display improved physiological stability, longer blood retention times, low acute toxicity and low immunogenicity. The tunable surface properties allow several types of functionality to be easily incorporated for imaging (optical, magnetic and nuclear), targeting and controlled delivery of cargo. This is synergistic with NPH's materials science platform.

"We are pleased to have licensed this technology. This further illustrates our ability and commitment to selectively add important technologies to our platform. This technology, developed by Dr. Tseng along with several other collaborators at UCLA has profound implications for drug delivery, gene transfection centering on siRNA, and companion diagnostics," stated Joseph A. Boystak, Chairman & Co-CEO.

"This technology should facilitate our ability to collaborate with a variety of corporate partners, research institutions and other academic researchers," said Michael Flesch, Vice Chairman & Co-CEO.

"I am pleased that my interaction and involvement with NPH will accelerate the development of the supramolecular nanoparticle systems toward applications in biology and medicine," said Dr. Tseng, Associate Professor, Molecular and Medical Pharmacology at UCLA.

####

About NanoPacific Holdings
NPH is a privately held research and development company based in Los Angeles, California focused on commercializing its unique patented nanotechnology portfolio which it has licensed from UCLA, UCSB and the Regents of the University of California. With its robust platform technologies and material sciences expertise, NPH is developing various precision-targeted, controlled delivery applications and products for the Biomedical, Cosmetics, Bio-industrial, Environmental and Food and Agricultural markets. NPH is developing a series of partnerships or joint ventures with corporate partners, research foundations, other high quality academic institutions and industry leaders in its target markets as a means to further develop and distribute these technologies and products, worldwide.

About the University of California at Los Angeles

UCLA is California’s largest university, with an enrollment of nearly 37,000 undergraduate and graduate students. The UCLA College of Letters and Science and the University’s 11 professional schools feature renowned faculty and offer more than 33 degree programs and majors. UCLA is a national and international leader in the breadth and quality of its academic, research, health care, cultural, continuing education and athletic programs. Four alumni and five faculty have been awarded the Nobel Prize.

For more information, please click here

Contacts:
Diego Benitez, Ph.D.

+1 310 268 9494 ext. 21

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: